Hydroxyurea to Prevent Organ Damage in Children With Sickle Cell Anemia

Status Completed

Clinical Trial Summary

The purpose of this study is to determine if hydroxyurea therapy is effective in the prevention of chronic end organ damage in pediatric patients with sickle cell anemia.

Clinical Trial Description

BACKGROUND:

In 1995, the Multicenter Study of Hydroxyurea (MSH) demonstrated that hydroxyurea is effective in decreasing the frequency of painful crises, hospitalizations for crises, acute chest syndrome, and blood transfusions by 50%. The recently completed phase II study of hydroxyurea in children (PED HUG) demonstrated that children have a response to hydroxyurea similar to that seen in adults in terms of increasing fetal hemoglobin levels and total hemoglobin, and decreasing complications associated with sickle cell anemia. In addition, this study demonstrated that the drug does not adversely affect growth and development between the ages of 5 and 15. A recently completed pilot study of hydroxyurea given to children between the ages of 6 months and 24 months demonstrated that the drug is tolerated well by small infant, and that the fetal hemoglobin switch can be forced to remain in the "on position" by hydroxyurea administration.

A Special Emphasis Panel (SEP) met on April 12, 1996 to review the results of the MSH trial and the progress to date of the PED HUG study. The SEP recommended that NHLBI undertake the BABY HUG trial.

DESIGN NARRATIVE:

BABY HUG is a randomized, double-blind, placebo-controlled study to determine if hydroxyurea can prevent the onset of chronic end organ damage in young children with sickle cell anemia. Approximately 200 children with sickle cell disease will be recruited to receive either hydroxyurea or placebo. The children will be screened at study entry for signs of abnormal brain, kidney, pulmonary, and splenic function, and developmental milestones. They will then be randomly assigned to receive either hydroxyurea or placebo and followed yearly to assess chronic end organ damage of the major organ systems. The primary endpoint will be a 50% reduction in rates of damage to the major organs with surrogate markers of organ function during follow-up in Phase II of the trial. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00006400
Study type	Interventional
Source	National Heart, Lung, and Blood Institute (NHLBI)
Contact
Status	Completed
Phase	Phase 3
Start date	August 2000
Completion date	September 2009

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04094844` - Health Information Technology System ("Roadmap 2.0") in the Context of Hematopoietic Cell Transplantation	N/A
Completed	`NCT04474678` - Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")	N/A
Recruiting	`NCT03918343` - Lipopolysaccharide Metabolism and Identification of Potential Biomarkers Predictive of Graft-versus-host Disease After Allogeneic Stem Cell Transplantation	N/A
Completed	`NCT01445561` - Ultra Low Dose Interleukin-2 in Healthy Volunteers	Phase 1
Recruiting	`NCT06148610` - Evaluation of the Impact of the Use of NewSpringForMe on Transplanted Patients' Quality of Life and Support
Completed	`NCT04168983` - Impact of Sophrology on the Pain Felt During a Bone Marrow Aspiration and Biopsy	N/A
Not yet recruiting	`NCT05969821` - Clonal Hematopoiesis of Immunological Significance
Withdrawn	`NCT04282174` - CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies	Phase 2
Completed	`NCT01108159` - Integrated Whole-Genome Analysis of Hematologic Disorders
Completed	`NCT00800839` - Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide	Phase 2
Completed	`NCT00213239` - A Dose Finding Study of Remifentanil and Propofol for Lumbar Punctures in Children	Phase 1/Phase 2
Terminated	`NCT00208949` - A Comparison of Dendritic Cell Content and T-Cell Phenotype Between Granulocyte Colony-Stimulating Factor (G-CSF) or G-CSF + Granulocyte Macrophage (GM)-CSF	Phase 2
Terminated	`NCT00176826` - T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders	Phase 2/Phase 3
Completed	`NCT00208962` - Allogeneic Cell Therapy for Adults With Hematologic Malignancies	Phase 2
Completed	`NCT00000603` - Cord Blood Stem Cell Transplantation Study (COBLT)	Phase 2
Completed	`NCT00000587` - Erythropoietin for Anemia Due to Zidovudine in Human Immunodeficiency Virus Infection	Phase 2
Active, not recruiting	`NCT03655678` - A Safety and Efficacy Study Evaluating CTX001 in Subjects With Transfusion-Dependent β-Thalassemia	Phase 2/Phase 3
Recruiting	`NCT05487794` - Effect of Dose Fractionation of Testosterone Cypionate on Transgender Men With Erythrocytosis	N/A
Completed	`NCT03611257` - Effect of dRAST on Treatment for Bacteremia in Patients With Hematologic Diseases	N/A
Completed	`NCT02827149` - High Resolution Donor Recipient HLA Matching Level in Unrelated HSCT

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.